## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.1% below STRENGTH zone (3.0-6.0%); PEG 1.03 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($87.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Amundi Sells 401,103 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251209T083506 | Neutral | Relevance: 99%
- Amundi significantly reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by selling 401,103 shares, decreasing its holdings by 38.7% in the second quarter. Despite this, other institutional investors have increased their positions in the medical equipment provider. Analysts currently rate Zimmer Biomet with a consensus "Hold" and a target price of $109.00.

**2. Gamco Investors INC. ET AL Buys 45,164 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251208T114459 | Neutral | Relevance: 98%
- Gamco Investors INC. ET AL increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 22.5%, purchasing 45,164 shares, bringing its total holdings to 245,955 shares valued at approximately $22.43 million. Other institutional investors also adjusted their positions in the medical equipment provider. Analysts currently have a mixed outlook on ZBH, with a consensus "Hold" rating and an average price target of $109.00, although recent target adjustments varied.

**3. Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by Invesco Ltd.**
- Source: MarketBeat | 20251206T112634 | Neutral | Relevance: 98%
- Invesco Ltd. recently increased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.5%, acquiring an additional 475,921 shares, bringing its total ownership to 4,606,591 shares valued at over $420 million. Other institutional investors also adjusted their stakes, while SVP Lori Winkler sold 1,500 shares. The company reported strong Q3 earnings, beating consensus estimates, and maintains an average analyst rating of "Hold" with a consensus target price of $109.00.

**4. Arrowstreet Capital Limited Partnership Purchases 42,196 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251206T083726 | Neutral | Relevance: 98%
- Arrowstreet Capital Limited Partnership increased its stake in Zimmer Biomet Holdings, Inc. by 8.9%, acquiring an additional 42,196 shares to bring its total to 514,920 shares valued at approximately $46.97 million. Other institutional investors have also adjusted their positions in the medical equipment provider. Despite mixed analyst sentiment and some firms lowering price targets, the company's recent quarterly earnings beat EPS estimates, though revenue was just below estimates, and it provided FY2025 guidance.

**5. Zimmer Biomet Holdings Inc. (ZBH) Stock Price | Live Quotes & Charts | NYSE**
- Source: StocksToTrade | 20251206T000837 | Neutral | Relevance: 97%
- This page provides live stock quotes and charts for Zimmer Biomet Holdings Inc. (ZBH) on the NYSE. It displays current price information, outlines the absence of recent analyst ratings and earnings data, and includes promotional content for a stock trading platform.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Canaccord Genui | $93 | $101 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Canaccord Genui | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($0.00M) |
| Sells | 2 ($0.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 6.2% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Forward P/E 10.9x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.4B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 10.9 |
| Current P/E | 11.4 |
| YoY Growth | 4.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.6% to -3.1% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.1pp (needs >3.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.08% (CS: 22) | Weak |
| RSI_14 | 45.8 | Neutral |
| MACD Histogram | 0.35 | Bullish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 0.964x | Below |
| vs SMA200 | 0.938x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $92.75
- **Stop Loss:** $87.91 (5.2% risk)
- **Target:** $97.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 103
- **Position Value:** $9,553.25
- **Portfolio %:** 9.55%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*